Law Firm Urges Investors in Navan and Corcept to Contact Them Before Deadlines

Bragar Eagel & Squire, P.C. reminds investors of upcoming lead plaintiff deadlines in class action lawsuits.

Mar. 31, 2026 at 7:48pm

Got story updates? Submit your updates here. ›

A minimalist studio still life photograph featuring a stack of legal documents, a gavel, and a pair of eyeglasses, conceptually representing the abstract themes of corporate litigation and shareholder rights.A law firm's call to action for investors who suffered losses in Navan and Corcept stock to join class action lawsuits before upcoming deadlines.NYC Today

Bragar Eagel & Squire, P.C., a national shareholder rights law firm, is reminding investors that class action lawsuits have been filed on behalf of stockholders of Navan, Inc. (NASDAQ: NAVN) and Corcept Therapeutics Incorporated (NASDAQ: CORT). The firm is urging investors with large losses in these companies to contact them before the upcoming lead plaintiff deadlines.

Why it matters

These class action lawsuits allege that the companies made false and misleading statements in their IPO documents or during the class period, which caused significant declines in their stock prices and resulted in losses for investors. The outcomes of these cases could impact the recoveries available to affected shareholders.

The details

The Navan lawsuit alleges the company's IPO documents were false and misleading by omitting information about increased sales and marketing expenses. Corcept is accused of misrepresenting the status of its new drug application for relacorilant, which the FDA later rejected. Both companies have seen their stock prices plummet as a result of these issues.

  • Navan's IPO was on October 30, 2025.
  • The lead plaintiff deadline for the Navan lawsuit is April 24, 2026.
  • The class period for the Corcept lawsuit is October 31, 2024 to December 30, 2025.
  • The lead plaintiff deadline for the Corcept lawsuit is April 21, 2026.

The players

Bragar Eagel & Squire, P.C.

A nationally recognized shareholder rights law firm with offices in New York, South Carolina, and California. The firm represents individual and institutional investors in securities, derivative, and commercial litigation.

Navan, Inc.

A company that conducted an initial public offering on October 30, 2025, selling approximately 36.9 million shares at $25.00 per share.

Corcept Therapeutics Incorporated

A pharmaceutical company that is developing a new drug candidate called relacorilant for the treatment of hypercortisolism, also known as Cushing's syndrome.

Got photos? Submit your photos here. ›

What they’re saying

“Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York, South Carolina, and California. The firm represents individual and institutional investors in securities, derivative, and commercial litigation as well as individuals in consumer protection and data privacy litigation.”

— Brandon Walker, Attorney

What’s next

Investors in Navan and Corcept have until the upcoming lead plaintiff deadlines to contact Bragar Eagel & Squire, P.C. to potentially serve as the lead plaintiff in the respective class action lawsuits.

The takeaway

These class action lawsuits highlight the importance for investors to carefully review company disclosures, especially around the time of an IPO or new drug application, to ensure they are not misled about a company's financial health or the status of its key products. Investors who suffered significant losses may be able to recover damages through these legal proceedings.